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(6.47-inﬁnity) were calculated or conﬁrmed and compared
among the studies. Variability was explained by the use of
different cut-offs, different reference methods (e.g. cDXA’s
measurement sites) and different subject’s populations.
CONCLUSIONS: Although the results of some studies appear
promising; further reﬁnement of indications, population-speciﬁc
reference databases and studies to determine valid cut-off are
needed before the technology can be successfully introduced into
routine care.
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OBJECTIVES: The objective of this study was to compare efﬁ-
cacy and safety of leﬂunomide with biological antirheumatic
drugs (adalimumab, etanercept, inﬂiximab, rituximab, anakinra)
in active rheumatoid arthritis. METHODS: Comparison was
based on systematic review, carried out according to guidelines
published by the Cochrane Collaboration and Agency for Tech-
nology Assessment in Poland. The most important medical data-
bases (EMBASE, MEDLINE, CENTRAL) were searched. Two
reviewers independently selected trials, assessed trial quality and
extracted data. No head to head trials were identiﬁed so indirect
comparison using Bucher’s method was performed. RESULTS:
The results of 33 randomized controlled trials were included in
indirect comparison. Leﬂunomide was shown to have better
ACR20 response than anakinra (RR = 1.44 [1.14; 1.81]) but no
signiﬁcant differences in ACR response were found in compari-
sons with other drugs. Comparisons of HAQ disability scores
indicate than leﬂunomide reduces disability better than adali-
mumab (WMD = -0.15; [-0.29; -0.01]), inﬂiximab (WMD =
-0.35 [-0.50; -0.20]), anakinra (WMD = -0.47 [-0.69; -0.25]),
rituximab (WMD = -0.38 [-0.59; -0.17]), but not etanercept
(WMD = -0.18 [-0.37; 0.01]). Radiographic improvement was
better in comparison with anakinra (WMD = -2.99 [-5.82;
-0.16]) and rituximab (WMD = -4.05 [-6.67; -1.43]) whereas
worse in comparison with adalimumab (WMD = 2.67 [0.87;
4.47]), etanercept (WMD = 1.75 [0.01; 3.49]) and inﬂiximab
(WMD = 2.06 [0.42; 3.70]). Leﬂunomid signiﬁcantly increases
the risk of treatment discontinuation due to the adverse events in
comparison with etanercept (RR = 3.50 [1.55; 7.88]). No signiﬁ-
cant differences in safety outcomes were noted between leﬂuno-
mid and other drugs. CONCLUSIONS: Indirect comparisons
indicate similar efﬁcacy of leﬂunomid, adalimumab, etanercept,
inﬂiximab or rituximab. Leﬂunomide seems to be more effective
than anakinra. Safety proﬁle of leﬂunomide is worse in compari-
son with etanercept, whereas in comparison with other analyzed
drugs no differences were found.
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OBJECTIVES: To estimate the cost-effectiveness relationship of
leﬂunomide compared to inﬂiximab, etanercept and adalimumab
for the treatment of patients with rheumatoid arthritis (RA) with
suboptimal response despite methotrexate (MTX) monotherapy.
METHODS: Time horizon was 24 weeks. Efﬁcacy data was
obtained from systematic review of published literature. The
model compares four groups: leﬂunomide, inﬂiximab, etanercept
and adalimumab, all in combination with MTX, under the per-
spective of Public Health Sector in Mexico. We included direct
costs of medications during 24 weeks and costs associated with
therapeutic failure due to adverse events or lack of efﬁcacy. In
those cases, we calculated initial treatment costs during 8 weeks,
and after treatment changed, it was estimated an average cost of
biological therapy for the 16 remaining weeks. The effectiveness
measure was the response rate according to the American College
of Rheumatology criteria (ACR). The analysis was conducted
using Tree Age Pro Suit 2006. RESULTS: The proportion of
patients reaching an ACR20 response was 50% for leﬂunomide,
53% for inﬂiximab, 61.6% for adalimumab and 67.9% for
etanercept. The expected costs of 24 weeks of treatment were
€891.2, €4274.5, €5054.5 and €4072.3 for leﬂunomide, inﬂix-
imab, adalimumab and etanercept, respectively. The cost per
patient with ACR20 improvement was €1781.8 for leﬂunomide,
€8205.8 for adalimumab, €8069.9 for inﬂiximab and €5996.7
for etanercept. The average cost per patient reaching an ACR50
or ACR70 response was also much lower for leﬂunomide
(€ 3,248.7, €8,999.2) than for the biological agents: etanercept
(€ 9492.6, €23,424.6), adalimumab (€ 12,290.4, €23,646.5),
inﬂiximab (€14,726.1, €40,349.5). CONCLUSIONS: Leﬂuno-
mide added to MTX is a cost-effective strategy compared to
inﬂiximab, adalimumab and etanercept, each one added to MTX
in patients with suboptimal response to MTX monotherapy.
Therefore, we recommend the use of leﬂunomide for patients
with refractory RA with suboptimal response to MTX, before
using a biological agent.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyal-
gia syndrome (FM) among the adult population in the general
population, in Germany, using the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ) and
American College of Rheumatology (ACR) classiﬁcation criteria.
METHODS: Every patients going to visit the rheumatologist in
Munchen hospital during a 30-days period, were interviewed
using the validated LFESSQ (4 items) with two additional ques-
tions on fatigue (LFESSQ 6 items), and examined to conﬁrm the
diagnostic of FM using ACR classiﬁcation criteria. The screening
questionnaire was also administered to a representative commu-
nity sample more than 15 years old, selected by the quota
method. The prevalence of FM was estimated in the general
population, applying the predictive positive value observed in
rheumatology consultation, to the positive screens, RESULTS:
A total of 52.6% patients interviewed in the rheumatology
department were screened positive for chronic widespread pain
(LFESSQ 4), 42.7% for widespread pain and fatigue (LFESSQ 6),
16.4%[15.8–16.9] were conﬁrmed FM cases. Based on positive
screens for chronic widespread pain and LFESSQ 4, the preva-
lence of FM in general population, is 5.8 % (95% IC: [4.3–7.2];
7.5% in females and in 3.8% males respectively). If fatigue is
added, the prevalence is 3.2 % (95% IC: [2.1–4.3] ; 3.9% in
females and 2.5% in males respectively). Prevalence rises with
age until the age group 75–84 years old. FM sufferers are females
wit an average age of 53.5 years old (SD: 12.4). CONCLU-
SIONS: Our ﬁndings are slightly higher than those obtained in
our study in France, Spain and Portugal, and those published in
Canada, US or Spain, probably due to the different methodolo-
gies and populations used. Symptoms of pain as fatigue must be
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perceived differently according to the individuals questioned. The
minimum prevalence estimated of 3.2% in Germany corresponds
to 2.26 million of FM sufferers.
PMS6
PREVALENCE OF FIBROMYALGIA IN FRANCE
Le Lay K1, Bannwarth B2, Blotman F3, Boussetta S1, Taieb C1
1Pierre Fabre, Boulogne, France, 2University Hospital Pellegrin,
Bordeaux, France, 3Lapeyronie Hospital, Montpellier, France
OBJECTIVES: Fibromyalgia syndrome (FM) is an under diag-
nosed disorder of unknown etiology. The prevalence rate is
thought to be about 2% in the general population, 5.8% of
women ages 40–60 and as high as 8% in women ages 55–64.
Recent European estimates are needed. This aim of the study was
to estimate the prevalence of FM in the general adult population,
in France and describe the socio-demographic characteristics of
patients. METHODS: The French validated version of the
London Fibromyalgia Epidemiology Study Screening Question-
naire (4 items relating to widespread pain and 2 items on fatigue)
was administered to a representative community sample of 1014
subjects aged over 15 years, selected by the quota method. The
questionnaire was submitted to a sample of rheumatology out-
patients (n = 178), who were then examined by a trained rheu-
matologist to conﬁrm or exclude the diagnosis of FM according
to the 1990 American College of Rheumatology criteria. The
prevalence of FM in the general population was estimated by
applying the predictive positive value to eligible community sub-
jects (i.e., positive screens). RESULTS: In the community sample,
9.8% and 5.0% screened positive for widespread pain without
and with fatigue, respectively. Among rheumatology outpatients,
47.1% and 34.8% were screened positive respectively, whereas
10.6% were conﬁrmed FM cases. Based on widespread criteria,
the prevalence of FM was estimated at 2.2 % (95% CI: 1.3%–
3.1%) in the French general population. The corresponding
ﬁgure was 1.4 % (95% CI, 0.7%–2.1%) if pain is added. FM
sufferers are females with an average age of 47.3 years old (SD:
12.4, 21.5–68.0). CONCLUSIONS: Our ﬁndings are in agree-
ment with those of earlier national survey reports. A point preva-
lence of 1.4% would translate in approximately 680,000 patients
with FM in France.
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OBJECTIVES: To assess the estimated prevalence of ﬁbro-
myalgia syndrome (FM) among the adult population in
United-Kingdom in the general population, using the London
Fibromyalgia Epidemiology Study—Screening Questionnaire
(LFESSQ) and American College of Rheumatology (ACR) clas-
siﬁcation criteria. METHODS: The LFES-SQ was administered
to a representative community sample of 1500 subjects aged over
15 years, selected by the quota method. A positive screen was
deﬁned as: (1) meeting the 4-pain criteria alone (LFESSQ-4), or
meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). The
positive predictive value of LFESSQ-4 and LFESSQ-6, was esti-
mated in different European countries, this questionnaire was
submitted to a sample of rheumatology outpatients (n = 1.125),
who were then examined by a trained rheumatologist to conﬁrm
or exclude the diagnosis of FM according to the 1990 American
College of Rheumatology criteria. The prevalence of FM in the
English general population was estimated by applying the pre-
dictive positive value to eligible community subjects (i.e., positive
screens) in UK. RESULTS: The community sample is constituted
of 765 females and 735 men. 7.8% screened positive for
LFESSQ-4 (9.3% in females and 6.3% in males respectively). A
total of 4.3% screened positive for LFESSQ-6 (5.5% in females
and 3.0% in males respectively). Based on positive screens for
LFESSQ 4 items (pain only), the prevalence of FM would be
estimated at 2.8% (95% CI: [1.9–3.6] ; 3.3% in females and
2.2% in males respectively). The corresponding ﬁgure was 1.8 %
(95% CI: [1.1–2.5] ; 2.3% in females and 1.3 % in males
respectively) if positive screens for LFESSQ-6 (pain and fatigue)
were considered. CONCLUSIONS: Our study conﬁrms the
results of publications in Canada, US or Spain, with slightly
differences probably due to the different methodologies and
populations used. A point prevalence of 1.8 % would translate in
approximately 880 thousands of patients with FM in UK.
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OBJECTIVES: To assess the estimated prevalence of possible
ﬁbromyalgia (FM) sufferers among the adult population in Italy
using a screening questionnaire, the London Fibromyalgia
Epidemiology Study—Screening Questionnaire (LFESSQ).
METHODS: Every patients going to visit a rheumatologist at a
hospital in Firenze, during a 30-day period, what the reason of
their visit, were interviewed using the LFESSQ with two addi-
tional questions on fatigue, and examined to conﬁrm or exclude
the diagnostic of FM using American College of Rheumatology
(ACR) classiﬁcation criteria. The screening questionnaire was
also administered to a representative community sample more
than 15 years old, selected by the quota method. The prevalence
of FM was estimated in the general population, applying the
predictive positive value, observed in consultation, to the positive
screens. RESULTS: 31.3 % patients interviewed were found posi-
tive for chronic widespread pain, 20.7% for widespread pain and
fatigue and in 26.2% [25.6–26.7] the diagnosis of FM was
conﬁrmed. In the general adult population, 10.1% subject were
positive for widespread pain and 5.2% for widespread pain and
fatigue. The prevalence in general population, is 6.6% [5.1–8.1],
if patients screened positive for chronic widespread pain are
considered. If fatigue is added, the prevalence of 3.7% [2.6–4.8].
Prevalence rises with age until the age group 75–84 years old. FM
sufferers are 84% females and an average age of 52.9 years old
(SD: 14.2). CONCLUSIONS: Our study conﬁrms the results
from Canada, US or Spain, with slight differences probably due
to the different methodologies and populations employed. The
minimum prevalence estimated of 3.6% in Italy, these means that
approximately 1.8 millions of Italians, largely women, may suffer
from FM.
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OBJECTIVES: To estimate the prevalence of ﬁbromyalgia syn-
drome (FM) in rheumatology consultation and in the general
adult population, in Portugal. METHODS: All patients going to
visit the rheumatologist in the Hospital Egas Moniz and in Hos-
pital Santa Maria in Lisbon during a 30-days period, were inter-
viewed using the London Fibromyalgia Epidemiological Study
(LFES) Screening Questionnaire, with two additional questions
on fatigue, and examined to conﬁrm or exclude the diagnostic of
FM using American College of Rheumatology (ACR) classiﬁca-
tion criteria. The screening questionnaire validated in Portuguese
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